ERYTech Pharma SA Sponsored ADR

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 2 4 , 20 22

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

ERYTECH to P resent at the H.C. Wainwright Global Investment Conference

ERYTECH to Present at the H.C. Wainwright Global Investment Conference

ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Gil Beyen – Chief Executive Officer Eric Soyer – Chief Financial and Chief Operating Officer Dr. Iman El-Hariry – Chief Medical Officer Conference Call Participants Boris Peaker – Cowen and Company Jacob Mekhael – Kempen & Co Operator Good day, and thank you for standing by.

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call Transcript

ERYTECH Provides Business and Financial Update for the First Quarter of 20 2 2

ERYTECH Provides Business and Financial Update for the First Quarter of 2022

ERYTECH Announces Filing of 202 1 Universal Registration Document and 202 1 Annual Report on Form 20-F , as well as its 2022 financial calendar

ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

Today, investors are pricing in a massive divestiture and long-term supply deal into the valuation of ERYTECH and ERYP stock. The post Why Is ERYTECH Pharma (ERYP) Stock Up Today?

Why Is ERYTECH Pharma (ERYP) Stock Up Today?

Ardelyx

Cenntro Inc

Here's what you need to know about trading penny stocks on April 25th The post Best Penny Stocks to Buy as April Ends? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy as April Ends? 3 to Watch Today

Erytech Pharma SA (NASDAQ: ERYP) has sold its US manufacturing facility to Catalent Inc (NYSE: CTLT) for $44.5 million. Catalent will acquire Erytech's commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, with 40 people.

Why Erytech Pharma Are Shares Moving Higher Today

Catalent acquired ERYTECH's U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 million

ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

Erytech Pharma SA (NASDAQ: ERYP) says that the results from the NOPHO sponsored Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL) patients are published in the British Journal of Haematology. The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological.

Why Erytech Pharma Shares Are Rising Today

ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

ERYTECH to Present Novel Vesiculation Approach at the 24 th M eeting of the European Red Cell Society

ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

ERYTECH to Participate in the Upcoming April Investor Conferences

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2021 Results - Earnings Call Transcript

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 20 2 1

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021

ERYTECH Announces P resentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

ERYTECH to Participate in the Upcoming January Virtual Investor Conferences

ERYTECH Announces $ 7.85 Million Registered Direct Offering

ERYTECH Announces $7.85 Million Registered Direct Offering

ERYTECH Announces P resentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI

ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI

Erytech Pharma SA (NASDAQ: ERYP) shares gained more than 40% during the premarket trading session. Investors are probably reacting to the U.S. patent covering methods of treating solid tumors by administering methioninase and asparaginase.

Why Are Erytech Pharma Shares Soaring Tuesday Premarket?

The stock price of Erytech Pharma SA (NASDAQ: ERYP) increased by over 40% pre-market today. This is why it happened.The stock price of Erytech Pharma SA (NASDAQ: ERYP) increased by over 40% pre-market today.

Erytech Pharma (ERYP) Stock: Why The Price Surged Today

ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q3 2021 Results - Earnings Call Transcript

ERYTECH Provides Business and Financial Update for the Third Quarter of 20 2 1

ERYTECH Provides Business and Financial Update for the Third Quarter of 2021

ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting

News for ERYTech Pharma SA Sponsored ADR Stock (ERYP)